Jay Heller, VP, Head of Capital Markets, Nasdaq In 2024, we proudly welcomed leading IPOs including Lineage, Kaspi.kz, Waystar, BrightSpring Health Services, and Onestream. You're in great company ...

Kestra will join what’s been a strong start to the year for U.S. healthcare IPOs with seven companies raising $1.1 billion ...

IPO activity looks likely to stay in an uptrend into mid-year – especially in the U.S. Of course, a lot can change over the course of a year, so we’ll be updating our Nasdaq IPO Pulses each ...

The company, which is set to hit the Nasdaq ... medtech IPO sector. Last year, medtech offerings were few and far between, though there were still successful IPOs. One example is health technology ...

On the other side of the healthcare industry, the pharmaceutical sector has already had its fair share of IPOs this year. Weight loss drug developer Metsera is targeting $289m in its Nasdaq IPO while ...

The deals add to a strong month for health care IPOs, coming on the heels of Beta ... s shares are expected to begin trading Friday on the Nasdaq Global Select Market under the symbol MTSR.

TOKYO and NEW YORK, Jan. 20, 2025 /PRNewswire/ -- Spirit Advisors LLC proudly announces the successful completion of the initial public offering (IPO) of PicoCELA Inc. (Nasdaq: PCLA), a pioneer in ...

That's where Jordan Saxe, the Nasdaq's head of healthcare listings, comes in. Saxe has advised on over 200 IPOs, and part of his job description is educating venture capital, private equity ...

Nasdaq (Nasdaq: NDAQ) announced today that in 2024, it welcomed 171 initial public offerings (IPOs), raising a total of $22.7 billion. A total of 123 operating companies and 48 SPACs listed on ...

Ascentage Pharma Group International (HK:6855) has released an update. Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter ...

Maze Therapeutics ( NASDAQ: MAZE) shares were trading largely flat following a $140M initial public offering. Shares of the kidney disease drug developer opened at $16 per share after being priced at ...

And based on our IPO Pulses, IPO activity looks likely to stay in an uptrend into mid-year – especially in the U.S. Of course, a lot can change over the course of a year, so we’ll be updating our ...